Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Novo Nordisk, currently carrying a Zacks Rank #3 (Hold), exhibits significant growth potential in the future. The recent pipeline and regulatory setbacks that caused the stock price to slide are ...